The implementation will occur as part of a multi-year agreement that aims to improve patient care by giving clinicians clinical decision-making support and access to data from relevant clinical trials.
Philips IntelliSpace Precision Medicine is a system that brings together genomic data, disease histology and patient phenotype to give clinicians a comprehensive picture of a patient.
The agreement between Miami Cancer Institute and Philips will also advance the former’s launch of the TruSight Tumor 170 next-generation sequencing testing service, in collaboration with Illumina and N-of-One. The Philips system will help with data capture and storage.
More articles on healthcare quality:
Why some hospitals are offering essential oils to surgery patients
Former CDC leader on bird flu threat: ‘We don’t know how the story’s going to end’
Hospitals send many patients home with ‘risky’ antibiotics, study finds
